Related references
Note: Only part of the references are listed.Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
Jing Nie et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance A case report
Hong Zhu et al.
MEDICINE (2019)
Camrelizumab: First Global Approval
Anthony Markham et al.
DRUGS (2019)
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost et al.
NATURE MEDICINE (2019)
A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Yuqin Song et al.
CLINICAL CANCER RESEARCH (2019)
Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China
Jing Huang et al.
CANCER (2019)
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
Jianming Xu et al.
CLINICAL CANCER RESEARCH (2019)
Anti-PD1 SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement
William J. J. Finlay et al.
MABS (2019)
Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210
Xuelian Chen et al.
CANCER BIOLOGY & MEDICINE (2019)
Safety, anti-tumour activity, and pharmacokinetics of fixed- dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
Hongnan Mo et al.
BRITISH JOURNAL OF CANCER (2018)
Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
Jing Huang et al.
CLINICAL CANCER RESEARCH (2018)
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
Wenfeng Fang et al.
LANCET ONCOLOGY (2018)
Eruptive cherry angiomas developing in a patient treated with ramucirumab
Pablo Espinosa Lara et al.
ACTA ONCOLOGICA (2018)
In situ click chemistry generation of cyclooxygenase-2 inhibitors
Atul Bhardwaj et al.
NATURE COMMUNICATIONS (2017)
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
V. R. Belum et al.
EUROPEAN JOURNAL OF CANCER (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
Shelley Ji Eun Hwang et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
N. Girard et al.
ANNALS OF ONCOLOGY (2015)
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
K. Fizazi et al.
ANNALS OF ONCOLOGY (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo et al.
JAMA DERMATOLOGY (2015)
Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.
Su Jin Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Identification of Serum Regression Signs in Infantile Hemangioma
Daniela D'Arcangelo et al.
PLOS ONE (2014)
Association of chemokines and prolactin with cherry angioma in a sulfur mustard exposed population - Sardasht-Iran cohort study
Nayere Askari et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2
N. C. Ton et al.
CLINICAL CANCER RESEARCH (2007)
Immune response: A possible role in the pathophysiology of hemangioma
Zhi-Jun Sun et al.
MEDICAL HYPOTHESES (2007)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Y Iwai et al.
INTERNATIONAL IMMUNOLOGY (2005)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
